Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Head & Neck 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Colorectal Neoplasms 17Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma, Hepatocellular 10Stomach Neoplasms 9Colonic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Thyroid Neoplasms 7Pancreatic Neoplasms 7Cholangiocarcinoma 7Breast Neoplasms 7Esophageal Neoplasms 6Sarcoma 5Neuroendocrine Tumors 5Lung Neoplasms 5Head and Neck Neoplasms 5Gastrointestinal Neoplasms 5Biliary Tract Neoplasms 5Adenocarcinoma 5Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Neoplasms by Site 4Lung Diseases 4Liver Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Bronchogenic 4

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Thyroid Carcinoma, Anaplastic × Gastrointestinal × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡